Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308344 | 0.80 | KDM4E (0.33) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL7910108 | 0.80 | HMGCR (0.33) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL11161149 | 0.79 | PIK3CD (0.39) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL10308343 | 0.77 | HMGCR (0.33) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL12835664 | 0.77 | HMGCR (0.33) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL10308339 | 0.77 | HMGCR (0.33) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL10308379 | 0.77 | HMGCR (0.33) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL17449479 | 0.76 | PIK3CD (0.35) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL22253948 | 0.76 | PIK3CD (0.31) | PIK3CDHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL10212337 | 0.76 | PIK3CD (0.31) | PIK3CDHMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117487113-A | Aqueous polyurethane emulsion and preparation method and application thereof | 上海华峰新材料研发科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117487113-A | Aqueous polyurethane emulsion and preparation method and application thereof | 上海华峰新材料研发科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| CN-102841504-B | Positive photosensitive resin composition and method for forming pattern using the same | CHI MEI CORP | 2015-03-25 | — | — | CN | disclosed |
| US-20130260402-A1 | ANTHRAX CARBOHYDRATES, SYNTHESIS AND USES THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (WASHINGTON D.C.) | 2013-10-03 | — | — | US | disclosed |
| US-8420607-B2 | Anthrax carbohydrates, synthesis and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120328799-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION AND METHOD FOR FORMING PATTERNS BY USING THE SAME | CHI MEI CORPORATION (TW) | 2012-12-27 | — | — | US | disclosed |
| CN-102841504-A | Positive photosensitive resin composition and method for forming pattern using the same | CHI MEI CORP | 2012-12-26 | — | — | CN | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008134398-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | PIK3CD 300/4885HMGCR 4502/4885CHRM1 518/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | PIK3CD 569/4885HMGCR 3288/4885CHRM1 4454/4885 |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | DPP4, PREP, PEPD | PIK3CD 2815/4885HMGCR 2060/4885CHRM1 4570/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | PIK3CD 1933/4885HMGCR 2113/4885CHRM1 4656/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | PIK3CD 284/4885HMGCR 4454/4885CHRM1 494/4885 |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | PIK3CD 1196/4885HMGCR 4569/4885CHRM1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.